Healthcare’s Valuation Reset Opens a Quality Entry Point

This GMO Focused Equity Insights report, authored by Tom Hancock, Hassan Chowdhry, and James Mendelson, examines whether healthcare’s recent underperformance has created a durable opportunity for quality-focused investors 

• Healthcare lagged the S&P 500 over the past year, yet long-term earnings growth, innovation, and demographic demand remain intact.

• Valuations have compressed to attractive levels, reflecting skepticism around policy, patents, and post-COVID normalization rather than deteriorating fundamentals.

• Secular growth areas—from GLP-1 therapies and life science tools to managed care and AI-enabled efficiency—offer selective upside with downside resilience.

Read the full report to assess how quality discipline may turn short-term pain into long-term portfolio advantage.